Checkpoint Inhibitor–Induced Rejection of a Liver Allograft: A Combination of Acute T Cell–Mediated and Antibody‐Mediated Rejection
Brian T. Lee, Brian H. Horwich, Shefali Chopra, Aaron Ahearn, Hyosun H. Han – 13 August 2019
Brian T. Lee, Brian H. Horwich, Shefali Chopra, Aaron Ahearn, Hyosun H. Han – 13 August 2019
Richard D. Khusial, Catherine E. Cioffi, Shelley A. Caltharp, Alyssa M. Krasinskas, Adina Alazraki, Jack Knight‐Scott, Rebecca Cleeton, Eduardo Castillo‐Leon, Dean P. Jones, Bridget Pierpont, Sonia Caprio, Nicola Santoro, Ayman Akil, Miriam B. Vos – 13 August 2019 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children, but diagnosis is challenging due to limited availability of noninvasive biomarkers.
Toru Ikegami, Tomoharu Yoshizumi, Yuriko Tsutsui, Noboru Harada, Shinji Itoh, Shohei Yoshiya, Daisuke Imai, Hideaki Uchiyama, Masaki Mori – 13 August 2019 – Management of portal vein thrombosis (PVT), especially advanced PVT involving the superior mesenteric vein (SMV), in living donor liver transplantation (LDLT) is challenging. There were 514 adults who underwent LDLT between 2005 and 2018 included in this retrospective study, and PVT was observed in 67 (13.0%) patients.
Rosa Martin Mateos, Agustín Albillos – 13 August 2019 – Bacterial infections are more frequent and severe in patients with advanced liver disease and, therefore, in liver transplant candidates. The increased risk of infection in these patients parallels the severity of the immune dysfunction associated with cirrhosis, which is related to systemic inflammation and progressive immunodeficiency.
Yuanyuan Yang, Xinzhuan Zhao, Ziyu Wang, Wangqin Shu, Lijie Li, Yuqi Li, Zhiwei Guo, Bo Gao, Sidong Xiong – 12 August 2019
Erwan Atcheson, Wenqin Li, Carly M. Bliss, Senthil Chinnakannan, Kathrin Heim, Hannah Sharpe, Claire Hutchings, Isabelle Dietrich, Dung Nguyen, Amit Kapoor, Michael A. Jarvis, Paul Klenerman, Eleanor Barnes, Peter Simmonds – 10 August 2019
Tapas Patra, Keith Meyer, Ratna B. Ray, Ranjit Ray – 10 August 2019
Karel P. Alcedo, Andres Guerrero, Venkatesha Basrur, Dong Fu, Monea L. Richardson, Joshua S. McLane, Chih‐Chiang Tsou, Alexey I. Nesvizhskii, Theodore H. Welling, Carlito B. Lebrilla, Carol A. Otey, Hong Jin Kim, M. Bishr Omary, Natasha T. Snider – 9 August 2019 – CD73, a cell‐surface N‐linked glycoprotein that produces extracellular adenosine, is a novel target for cancer immunotherapy. Although anti‐CD73 antibodies have entered clinical development, CD73 has both protumor and antitumor functions, depending on the target cell and tumor type.
This webinar will review the latest approaches in the management of the immunosuppressed patient in the context of HBV reactivation, including screening, risk stratification and indication for antiviral treatment. The focus of management will be on both the oncologic and non-oncologic patient.
Wen‐Zhi Guo, Hong‐Bo Fang, Sheng‐Li Cao, San‐Yang Chen, Jie Li, Ji‐Hua Shi, Hong‐Wei Tang, Yi Zhang, Pei‐Hao Wen, Jia‐Kai Zhang, Zhi‐Hui Wang, Xiao‐Yi Shi, Chun Pang, Han Yang, Bo‐Wen Hu, Shui‐Jun Zhang – 8 August 2019